Mesoblast (MEOBF) Consolidated Net Income (2014 - 2023)
Mesoblast's (MEOBF) quarterly Consolidated Net Income came in at -$21.6 million in Q2 2023, down 113.31% year-over-year from $162.1 million in Q2 2022, and down 15.42% quarter-over-quarter from -$18.7 million in Q1 2023.
Analysis
Mesoblast (MEOBF) Consolidated Net Income (2014 - 2023) Analysis & Trends
Mesoblast has disclosed Consolidated Net Income across 10 years of filings, most recently posting -$21.6 million for Q2 2023.
- In Q2 2023, Consolidated Net Income fell 113.31% year-over-year to -$21.6 million; the TTM figure through Jun 2023 stood at -$81.9 million (down 189.18% YoY), while the FY2026 annual figure was $56.3 million, down 44.55% from the prior year.
- Consolidated Net Income came in at -$21.6 million for Q2 2023 at Mesoblast, down from -$18.7 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $178.7 million in Q2 2021 to a low of -$57.6 million in Q1 2020.
- Average Consolidated Net Income over 5 years is -$3.0 million, with a median of -$24.6 million recorded in 2022.
- Year-over-year, Consolidated Net Income soared 55.32% in 2019 and tumbled 178.18% in 2020.
- Over 5 years, Consolidated Net Income stood at -$38.5 million in 2019, then jumped by 33.6% to -$25.5 million in 2020, then declined by 2.2% to -$26.1 million in 2021, then advanced by 5.66% to -$24.6 million in 2022, then increased by 12.4% to -$21.6 million in 2023.
- Per Business Quant data, the three most recent Consolidated Net Income figures were -$21.6 million in Q2 2023, -$18.7 million in Q1 2023, and -$24.6 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.42 Bn | 112.79 Mn | 54.77 Mn |
| 2 | CRISPR Therapeutics AG | 5.20 Bn | 5.20 Bn | - | -91.19 Mn |
| 3 | Iovance Biotherapeutics | 3.78 Bn | 3.49 Bn | 55.72 Mn | -47.29 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 77.80 Mn |
| 5 | uniQure | 3.06 Bn | 3.06 Bn | 5.49 Mn | -81.06 Mn |
| 6 | Beam Therapeutics | 2.68 Bn | 2.68 Bn | - | -119.07 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 20.07 Mn |
| 8 | Sarepta Therapeutics | 2.35 Bn | 1.55 Bn | 251.87 Mn | -4.89 Mn |
| 9 | Vericel | 2.00 Bn | 1.83 Bn | 56.40 Mn | 2.23 Mn |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | -21.58 Mn |
| Mar 31, 2023 | -18.69 Mn |
| Dec 31, 2022 | -24.63 Mn |
| Sep 30, 2022 | -16.99 Mn |
| Jun 30, 2022 | 162.09 Mn |
| Mar 31, 2022 | -21.39 Mn |
| Dec 31, 2021 | -26.11 Mn |
| Sep 30, 2021 | -22.77 Mn |
| Jun 30, 2021 | 178.71 Mn |
| Mar 31, 2021 | -26.71 Mn |
| Dec 31, 2020 | -25.54 Mn |
| Sep 30, 2020 | -26.00 Mn |
| Mar 31, 2020 | -57.65 Mn |
| Dec 31, 2019 | -38.47 Mn |
| Sep 30, 2019 | -9.35 Mn |
| Jun 30, 2019 | -27.08 Mn |
| Mar 31, 2019 | -29.38 Mn |
| Dec 31, 2018 | -30.33 Mn |
| Sep 30, 2018 | -20.92 Mn |
| Jun 30, 2018 | -22.88 Mn |